| Price | 1,671.60on 20-09-2019 at 16:30:00 |
|---|---|
| Change | 13.80 0.83% |
| Buy | 1,660.20 |
| Sell | 1,659.20 |
| Buy / Sell GSK Shares | |
| Last Trade: | Buy 1,433 at 1,667.74p |
| Day's Volume: | 17,303,620 |
| Last Close: | 1,657.80p |
| Open: | 1,649.20p |
| ISIN: | GB0009252882 |
| Day's Range | 1,646.40p - 1,678.20p |
| 52wk Range: | 1,408.80p - 1,767.00p |
| Market Capitalisation: | £82,677m |
| VWAP: | 1,671.461p |
| Shares in Issue: | 4,946m |
Sector: Medicine and Biotech Research
Listed in: FTSE 100, FTSE All-Share, FTSE 350, FTSE 350 High Yield
Recent Trades History Glaxosmithkline (GSK) |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 1,433 | 1,667.74 | Ordinary | 18:45:05 - 20-Sep-19 |
| Buy* | 1,785 | 1,667.74 | Ordinary | 18:45:04 - 20-Sep-19 |
| Buy* | 2,478 | 1,671.521 | Ordinary | 18:45:06 - 20-Sep-19 |
| Buy* | 1,205 | 1,667.75 | Ordinary | 18:45:04 - 20-Sep-19 |
| Buy* | 122,724 | 1,671.60 | Ordinary Delayed publication | 17:25:11 - 20-Sep-19 |
| Buy* | 348,292 | 1,670.764 | Ordinary | 18:28:11 - 20-Sep-19 |
| Buy* | 10,470 | 1,671.521 | Ordinary | 17:58:41 - 20-Sep-19 |
| Buy* | 6,947 | 1,671.521 | Ordinary | 17:58:41 - 20-Sep-19 |
| Sell* | 1,006 | 1,658.799 | Ordinary | 17:48:46 - 20-Sep-19 |
| Sell* | 7,192 | 1,658.849 | Ordinary | 17:48:46 - 20-Sep-19 |
Share Price History for Glaxosmithkline |
|||||
| Date | Open | High | Low | Close | |
|---|---|---|---|---|---|
| 18th Sep 2019 (Wed) | 1,646.20 | 1,651.00 | 1,639.60 | 1,647.10 | |
| 17th Sep 2019 (Tue) | 1,631.40 | 1,652.40 | 1,628.80 | 1,647.60 | |
| 16th Sep 2019 (Mon) | 1,625.00 | 1,642.40 | 1,622.40 | 1,632.30 | |
| 13th Sep 2019 (Fri) | 1,656.80 | 1,660.40 | 1,631.60 | 1,644.50 | |
| 12th Sep 2019 (Thu) | 1,653.00 | 1,669.60 | 1,641.40 | 1,659.60 | |
| 11th Sep 2019 (Wed) | 1,654.80 | 1,655.80 | 1,626.80 | 1,648.20 | |
| 10th Sep 2019 (Tue) | 1,656.40 | 1,664.40 | 1,622.40 | 1,636.50 | |
| 9th Sep 2019 (Mon) | 1,722.80 | 1,731.60 | 1,668.80 | 1,673.70 | |
| 6th Sep 2019 (Fri) | 1,706.40 | 1,719.20 | 1,696.00 | 1,712.80 | |
| 5th Sep 2019 (Thu) | 1,745.00 | 1,746.20 | 1,701.80 | 1,704.80 | |
| 4th Sep 2019 (Wed) | 1,753.80 | 1,767.00 | 1,735.60 | 1,741.80 | |
| 3rd Sep 2019 (Tue) | 1,745.20 | 1,755.20 | 1,734.20 | 1,743.60 | |
| 2nd Sep 2019 (Mon) | 1,712.00 | 1,744.80 | 1,701.00 | 1,736.90 | |
| 30th Aug 2019 (Fri) | 1,714.60 | 1,720.40 | 1,707.80 | 1,711.60 | |
| 29th Aug 2019 (Thu) | 1,690.00 | 1,716.00 | 1,682.60 | 1,694.00 | |
| 28th Aug 2019 (Wed) | 1,685.00 | 1,704.40 | 1,672.80 | 1,694.00 | |
| 27th Aug 2019 (Tue) | 1,690.80 | 1,695.00 | 1,672.80 | 1,687.20 | |
| 26th Aug 2019 (Mon) | 0 | 0.00 | 0.00 | 1,695.30 | |
| 23rd Aug 2019 (Fri) | 1,692.60 | 1,698.60 | 1,687.80 | 1,672.60 | |
| 22nd Aug 2019 (Thu) | 1,679.60 | 1,686.40 | 1,667.80 | 1,672.60 | |
| 21st Aug 2019 (Wed) | 1,663.20 | 1,685.00 | 1,659.60 | 1,679.40 | |
| 20th Aug 2019 (Tue) | 1,669.40 | 1,680.60 | 1,660.80 | 1,662.80 | |
GlaxoSmithKline, or 'GSK', is one of the world's leading pharmaceutical companies researching medicines and vacines alike for the World Health Organization's three priority diseases: HIV/AIDS, Malaria and Tuberculosis. With an estimated 7% of the world's pharmaceutical market under its wing, GSK remains one of the industry leaders globally but remains committed to the research and application of life changing and marketable drugs.
If investing in science seems a little confusing and unpredictable then perhaps some of GSK's over-the-counter and more recognisable products will help to convince; these include Gaviscon and Panadol, smoking control products such as Nicorette/Niquitin and nutritional healthcare drinks such as Lucozade, Ribena and Horlicks.
On 23rd January 2009, GSK announced that it had signed an agreement with UCB S.A to acquire its marketed product portfolio in certain parts of the Middle East, Africa, Latin America and Asia Pacific, for a cash consideration of some £484 million. President of Emerging Markets at GSK, Abbas Hussain, said that "This acquisition will strengthen and expand GSK's product portfolio in these countries, helping us to meet the needs of patients, particularly in the areas of epilepsy and respiratory." Under the agreement, GSK acquires several leading pharmaceutical brands and investors will be interested to know that the commercial operations and product distribution rights included represent approximately 3-4% of UCB's 2008 expected revenue of at least £3.09 billion. At the time of Mr Hussain speaking, share prices for GSK were steady at 1,226.00p with a "strong buy" recommendation from brokers.
News - Wednesday, March 13, 2019
Emma Walmsley, the chief executive of GlaxoSmithKline, was awarded a £1 million pay rise last year, which took her total pay package, including bonuses, to almost £6 million. Walmsley is now thought to be the highest-paid female chief in a FTSE 100 company....
News - Tuesday, November 28, 2017
The FTSE 100 slipped by 25.74 points - a fall of 0.35 percent, during Monday afternoon’s trading. The biggest gainer on the index was GlaxoSmithKline, who gained 1.77 percent after UBS lifted its rating from ‘neutral’ to ‘buy’....
